Results 261 to 270 of about 1,262,540 (308)
Effect of Conization Prior to Radical Hysterectomy on Overall and Progression-Free Survival in Early-Stage Cervical Cancer: A Propensity Score-Matched Analysis. [PDF]
Cancers (Basel)Rachadech N, Phookiaw S, Charoenkwan K.
europepmc +1 more source
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study. [PDF]
Cancer Res CommunWang R +9 more
europepmc +1 more source
Osimertinib prolongs progression‐free lung cancer survival after chemotherapy
CA: A Cancer Journal for Cliniciansopenaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Concordance index: Surrogacy of progression-free survival for overall survival
Contemporary Clinical Trials, 2021In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire +2 more sources
Progression/Recurrence-Free Survival 2 in Adjuvant Melanoma
NEJM Evidence, 2022The long-term outcome of patients with stage III melanoma - that is, melanoma that has spread to nearby lymph nodes, lymphatics, or skin - who have received treatment with immune checkpoint inhibitors is of substantial interest. The article by Eggermont et al.1 published in this issue of NEJM Evidence reports 5-year outcomes from the stage III melanoma
Ryan C, Augustin, Jason J, Luke
openaire +2 more sources
Progression-Free Survival: Meaningful or Simply Measurable?
Journal of Clinical Oncology, 2012The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of ...
Christopher M, Booth +1 more
openaire +2 more sources
The Cancer Journal, 2009
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
David, Lebwohl +4 more
openaire +2 more sources
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
David, Lebwohl +4 more
openaire +2 more sources